Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells 1,763 Shares of Stock

Key Points

• Krista Davis, Senior Vice President of ANI Pharmaceuticals, sold 1,763 shares at an average price of $91.10, reducing her ownership by 2.73% and leaving her with approximately 62,896 shares valued at about $5.73 million.
• ANI Pharmaceuticals reported $1.80 earnings per share for the last quarter, exceeding estimates by $0.38, with quarterly revenue up 53.2% year-over-year.
• Analysts currently have an average price target of $84.75 for ANI Pharmaceuticals, with the stock rated predominantly as a Buy or Strong Buy by several research firms.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Krista Davis sold 1,763 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $91.10, for a total transaction of $160,609.30. Following the completion of the transaction, the senior vice president directly owned 62,896 shares in the company, valued at approximately $5,729,825.60. The trade was a 2.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

ANI Pharmaceuticals Trading Down 0.8%

Shares of ANIP stock traded down $0.69 during trading hours on Monday, reaching $90.32. The company had a trading volume of 351,712 shares, compared to its average volume of 373,533. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $92.65. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -117.30 and a beta of 0.61. The company has a 50 day moving average of $70.63 and a 200 day moving average of $65.99.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same quarter in the prior year, the firm posted $1.02 earnings per share. The company's quarterly revenue was up 53.2% on a year-over-year basis. On average, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co grew its position in ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company's stock valued at $1,267,000 after purchasing an additional 198 shares in the last quarter. Hohimer Wealth Management LLC grew its holdings in shares of ANI Pharmaceuticals by 5.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock valued at $334,000 after acquiring an additional 247 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of ANI Pharmaceuticals by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company's stock valued at $3,048,000 after acquiring an additional 351 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of ANI Pharmaceuticals by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock valued at $582,000 after acquiring an additional 364 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of ANI Pharmaceuticals by 10.0% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,368 shares of the specialty pharmaceutical company's stock valued at $285,000 after acquiring an additional 396 shares during the last quarter. Institutional investors own 76.05% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on ANIP. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Truist Financial lifted their target price on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a report on Monday, August 11th. HC Wainwright reaffirmed a "buy" rating and set a $93.00 price target (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Guggenheim reiterated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, Piper Sandler reissued an "overweight" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $84.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.